Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ASKA Pharmaceutical Holdings CoTSE:4886 +1.40%61 Return-on-Tangible-Equity is 9.19% as of Mar. 2026, which is 1% below its 10-year median of 9.30. GuruFocus rates TSE:4886 with a GF Score™ of 61/100 and a GF Value™ of 円2,402.15 (Fairly Valued). Among 901 Drug Manufacturers companies, ASKA Pharmaceutical Holdings Co ranks better than 54.05% on this metric.
The historical rank and industry rank for ASKA Pharmaceutical Holdings Co's Return-on-Tangible-Equity or its related term are showing as below:
TSE:4886'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 8.94 Med: 9.3 Max: 13.83
Current: 9.25
During the past 5 years, ASKA Pharmaceutical Holdings Co's highest Return-on-Tangible-Equity was 13.83%. The lowest was 8.94%. And the median was 9.30%.
TSE:4886's Return-on-Tangible-Equity is ranked better than 54.05% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs TSE:4886: 9.25
ASKA Pharmaceutical Holdings Co (TSE:4886) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
ASKA Pharmaceutical Holdings Co Return-on-Tangible-Equity Related Terms
ASKA Pharmaceutical Holdings Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASKA Pharmaceutical Holdings Co Return-on-Tangible-Equity Chart
TSE:4886 vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ASKA Pharmaceutical Holdings Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ASKA Pharmaceutical Holdings Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ASKA Pharmaceutical Holdings Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where ASKA Pharmaceutical Holdings Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 9.19% mean?
ASKA Pharmaceutical Holdings Co (TSE:4886) has a Return-on-Tangible-Equity of 9.19% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ASKA Pharmaceutical Holdings Co and its competitors. This is near median its historical median of 9.30. Over the past decade, ASKA Pharmaceutical Holdings Co's Return-on-Tangible-Equity has ranged from 8.94 to 13.83. According to the industry distribution chart, ASKA Pharmaceutical Holdings Co ranks #414 out of 901 companies in the Drug Manufacturers industry, placing it in the top 45.9%.
Is ASKA Pharmaceutical Holdings Co's Return-on-Tangible-Equity too high?
ASKA Pharmaceutical Holdings Co's current Return-on-Tangible-Equity of 9.19% is near median its 10-year median of 9.30. Over the past 10 years, this metric has ranged from a low of 8.94 to a high of 13.83. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. ASKA Pharmaceutical Holdings Co's value of 9.19% is 16.3% above this industry median. Based on the distribution chart, ASKA Pharmaceutical Holdings Co ranks #414 out of 901 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ASKA Pharmaceutical Holdings Co has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ASKA Pharmaceutical Holdings Co's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ASKA Pharmaceutical Holdings Co ranks #414 out of 901 companies for Return-on-Tangible-Equity. This puts ASKA Pharmaceutical Holdings Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. ASKA Pharmaceutical Holdings Co's value of 9.19% is 16.3% above this benchmark. Historically, ASKA Pharmaceutical Holdings Co's own Return-on-Tangible-Equity has ranged from 8.94 to 13.83 over the past decade. While the company's 10-year median is 9.30 vs. the industry median of 7.90, ASKA Pharmaceutical Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ASKA Pharmaceutical Holdings Co's current Return-on-Tangible-Equity of 9.19% is 16.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ASKA Pharmaceutical Holdings Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ASKA Pharmaceutical Holdings Co's current Return-on-Tangible-Equity is 9.19%, which is near median its own 10-year median of 9.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ASKA Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co (TSE:4886) is currently considered Fairly Valued. The stock's GF Value™ is 円2,402.15, compared to a current price of 円2,244.00 — trading 6.6% below its estimated fair value. The current Return-on-Tangible-Equity is 9.19%, which is near median its 10-year median of 9.30 and 16.3% above the Drug Manufacturers industry median of 7.90. ASKA Pharmaceutical Holdings Co's overall GF Score™ is 61/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For ASKA Pharmaceutical Holdings Co (TSE:4886), the current Return-on-Tangible-Equity is 9.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ASKA Pharmaceutical Holdings Co (TSE:4886) Overvalued in 2026?
Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of 円2,244.00 is trading 6.6% below its estimated GF Value™ of 円2,402.15.
GuruFocus considers ASKA Pharmaceutical Holdings Co to be Fairly Valued.
Key valuation signals for TSE:4886:
Return-on-Tangible-Equity: 9.19% (near median its 10-year median of 9.30)
GF Value™: 円2,402.15 vs. price of 円2,244.00 (6.6% below fair value)
Industry Position: 16.3% above the Drug Manufacturers median (#414 of 901)
No single metric tells the full story. See the TSE:4886 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ASKA Pharmaceutical Holdings Co Business Description
ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and other related operations.
61GF Score
Get the complete analysis for TSE:4886
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4886 has been successfully added to your 
